

University of Washington / Seattle Cancer Care Alliance

Name of the Research Study

Phase 2 Study of Azixa™ (MPC-6827) for the Treatment of Patients with Recurrent Glioblastoma Multiforme

Purpose of the Research Study

- The purpose of this study is to test the safety of the study drug, Azixa, in patients with first or second recurrence of glioblastoma multiforme
- To see how well patients tolerate the Azixa.
- The anti-tumor effects of Azixa in the treatment of glioma, a brain tumor, will be studied.

Protocol Summary

- Patients will be treated with Azixa™ (MPC-6827) once weekly for 3 consecutive weeks every 4 weeks. Treatment will continue until disease progression or unacceptable toxicity.
- Additional infusions may be given depending upon the response to the study drug.

Basic Eligibility Criteria

- Patients with first or second recurrence of glioblastoma multiforme
- Adults 18 years and older.
- Other criteria will be evaluated by the physician, nurse, and study coordinator to be sure the study is right for you.

Study Site Location

This research study is conducted at the University of Washington Medical Center and Seattle Cancer Care Alliance.

Contact Information

- Sandra K Johnston, PhD, RN 206.288.6365